Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

SYGNIS Reports Financial Results for Fiscal Year 2011/2012

Published: Friday, October 05, 2012
Last Updated: Friday, October 05, 2012
Bookmark and Share
Financing secured until March 2013.

SYGNIS Pharma AG has reported results for the fiscal year 2011/2012 ending on March 31, 2012.

In the past twelve months, focus of the business operations was on the clinical development of its drug candidate AX200 for the treatment of acute stroke and further development of the pre-clinical KIBRA project.

Additionally, SYGNIS examined options to extend its pipeline, possibly with strategic partnerships or business transactions. Following the negative AXIS 2 results and termination of the development project AX200 these activities were intensified.

In this context, SYGNIS has signed a binding term sheet with GENETRIX, after period end, to combine SYGNIS with GENETRIX’s subsidiary X-Pol Biotech S.L.

X-Pol Biotech is active in the field of DNA sequencing. The goal is to further develop and market X-Pol Biotech’s DNA sequencing technologies and products.

Peter Willinger, Chief Financial Officer, comments: “The fiscal year 2011/2012 was characterized by the completion of the AXIS 2 trial in December 2011. Data published did not show sufficient efficacy of AX200 in the treatment of stroke patients. Since this ruled out the commercialization of AX200, we had to completely write off the project. At the same time, we explored different opportunities for a strategic realignment of the Company and were able to announce a first success in July. After the planned merger with X-Pol Biotech, SYGNIS will continue to operate in the biotech sector, but with a new focus, a lower risk profile and the opportunity to generate revenues already in the short term.”

Net loss in fiscal 2011/2012 amounted to -€17.4 million (2010/11: -€12.4 million). This further decline in net loss resulted mainly from an impairment loss of goodwill and other intangible assets of €20.2 million in connection with the discontinuation of the AX200 project.

This was partially offset by income from the purchase of an outstanding loan. With effect as of March 31, 2012, SYGNIS had purchased the claims combined with the loan amounting to €8.0 million for a price of €1.00 from BASF SE and thus realized gains of €8.0 million.

R&D expenditure was down by €3.9 million to €6.6 million (2010/11: €10.5 million). The decrease in R&D expenses mainly resulted from a higher level of investment in the AXIS 2 trial in the previous year and reduced personnel expenditure due to restructuring measures executed in the previous year.

Results from available-for-sale financial investments increased to €0.8 million (2010/11: -€0.1 million). This was mainly due to realized gains from the sale of shares in Noema Life S.p.A.

Income taxes include income of €2.0 million due to the reversal of deferred tax liabilities (2010/11: €0.3 million). Impairment losses on intangible assets, following termination of the AX200 project, led to a reduction of corresponding deferred tax liabilities.

Cash outflow from operating activities was up from €8.3 million in the previous year to €8.7 million. Though other operating expenses were reduced in the reporting period, a part of the expenditure of the previous year only affected liquidity in fiscal year 2011/2012.

Cash flow from investing activities was positive and amounted to €2.4 million (2010/11: €0.9 million), mainly caused by the sale of securities. Due to the capital increase, cash flow from financing activities increased to €6.1 million (2010/11: €0.0 million).

Cash and cash equivalents including available-for-sale securities were €4.2 million (2010/11: €6.8 million) as at March 31, 2012. Long-term debt was reduced from €10.8 million to €0.6 million as a result of the loan acquired from BASF SE and the reduction of deferred tax liabilities. Short-term debt was also down, decreasing from €3.8 million to €2.2 million.

Compared to the previous year, the balance sheet total was down from €32.3 million to €8.6 million, primarily due to the impairment losses of intangible assets.

As a result of the net loss for the year, equity was down to €5.7 million (2010/11: €17.7 million). Equity ratio was 66%, accordingly (2010/11: 55%).

For the current financial year 2012/2013 emphasis is being placed on securing sufficient funding and the further implementation of the strategic realignment through the proposed merger with X-Pol Biotech. With this merger and the marketing of existing products and technologies, SYGNIS expects to generate initial revenues.

For the KIBRA project SYGNIS is looking for a pharma partner. The Company has therefore started a systematic partnering process and is in ongoing discussions with potential partners for the project.

However, should the Company not succeed in winning a partner for KIBRA, the management will have to reconsider the future of this project.

The Company’s available financial assets as of March 31, 2012 secure the liquidity of SYGNIS until approximately March 2013. This estimation does not include revenues that may result from potential research co-operations for the KIBRA project. To further finance its business activities, the Company will have to rely on further funding from March 2013 on.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SYGNIS Further Strengthens its Patent Position for AX200 for the Treatment of Stroke
European Patent Office has given two notices regarding intention to issue additional AX200-patents shortly.
Saturday, September 17, 2011
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos